
CITATION REPORT List of articles citing



DOI: 10.1016/0021-9150(81)90103-9 Atherosclerosis, 1981, 38, 51-61.

Source: https://exaly.com/paper-pdf/15006772/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
624	Apolipoprotein and Cholesterol but not Lipoprotein(a) Serum Concentrations Are Modulated by Thyroxine. 1993 , 119-123		1
623	Experience with low-density lipoprotein apheresis by polyclonal and monoclonal anti-apolipoprotein B antibodies and by dextran sulfate cellulose. 1990 , 57, 208-19		5
622	Comparison of Lipoproteins between Chimpanzees and Humans. 1994 , 134-142		
621	Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts. 1981, 132, 169-73		89
620	Population-based lipoprotein lipid reference values for pregnant women compared to nonpregnant women classified by sex hormone usage. 1982 , 143, 626-37		90
619	Apoprotein B of lipoprotein(a) of human plasma. 1982 , 208, 393-8		10
618	Discriminative value of lipids and apoproteins in coronary heart disease. <i>Atherosclerosis</i> , 1982 , 42, 197-	2 <u>0</u> 31	168
617	Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. <i>Atherosclerosis</i> , 1982 , 44, 61-71	3.1	142
616	High Density Lipoproteins: Composition, Analysis, and Significance for Risk Screening and Anti-Risk Factors for Atherosclerosis. 1982 , 267-278		
615	[The apolipoproteins in man]. 1982 , 60, 673-49		5
614	[Apolipoproteinopathies]. 1983, 61, 169-82		9
613	Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus. <i>Atherosclerosis</i> , 1983 , 49, 277-93	3.1	89
612	Protein composition of Lp(a) lipoprotein from human plasma. 1983 , 154, 357-61		189
611	The determination of lipoprotein Lp(a) by rate and endpoint nephelometry. 1983, 135, 203-8		46
610	A rapid screening method for pathological lipoprotein Lp(a) concentrations by counterimmunoelectrophoresis. 1983 , 128, 373-8		16
609	Quantification of human serum lipoprotein Lp(a): zone immunoelectrophoresis assay, a new sensitive method as compared to electroimmuno assay. 1983 , 134, 265-79		22
608	Familial study on "sinking pre-beta", the Lp(a) lipoprotein, and its relationship with serum lipids, apolipoprotein A-I and B and clinical atherosclerosis. 1983 , 21, 267-72		

607	Serum apolipoproteins and lipoprotein (a) during the first week of life. 1983, 72, 505-9	29
606	Apoproteins B and A-I and coronary artery disease in humans. 1984 , 4, 79-83	278
605	Double labeling of lipoprotein receptors in fibroblast cell surface replicas. 1984 , 87, 149-58	12
604	Total plasma apo E and high density lipoprotein apo E in survivors of myocardial infarction. Atherosclerosis, 1984 , 53, 69-75	29
603	Serum lipids and lipoproteins in patients with primary gout. 1985 , 5, 73-7	12
602	[Different levels of lipoprotein Lp(a) in adult diabetic patients depending on the therapeutic regimen]. 1985 , 63, 648-50	5
601	Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. 1985 , 5, 265-72	225
600	Plasma lipoproteins, apolipoproteins, and proteins concerned with lipid metabolism. 1985 , 24, 217-98	10
599	Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. <i>Atherosclerosis</i> , 1985 , 57, 293-30 9 .1	248
598	Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus. 1985 , 79, 86-91	12
597	Characterization of an unusual lipoprotein similar to human lipoprotein a isolated from the baboon, Papio sp. 1986 , 877, 75-8	33
596	Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). 1986 , 64, 999-1009	84
595	Delayed effects of prolonged exercise on serum lipoproteins. 1986 , 35, 105-9	59
594	Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum. 1986 , 35, 333-6	71
593	Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. 1986 , 74, 758-65	847
592	Effect of cervical spinal cord lesions on early components of the median nerve somatosensory evoked potential. 1986 , 36, 20-6	50
591	SHORT COMMUNICATION/KURZMITTEILUNG. 1986 , 24,	
590	Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. 1987 , 368, 1533-44	104

589	Chapter 4 Lipoprotein(a): structure, metabolism and epidemiology. 1987, 129-152		19
588	Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. <i>Atherosclerosis</i> , 1987 , 68, 1-17	3.1	143
587	Effect of insulin therapy on lipoproteins in non-insulin dependent diabetes mellitus (NIDDM). <i>Atherosclerosis</i> , 1987 , 67, 105-14	3.1	27
586	Free and Apo B-associated Lpa-specific protein in human serum. 1987 , 164, 93-100		56
585	Black-white differences in serum Lp(a) lipoprotein levels. 1987 , 168, 27-31		81
584	Characterization of apoprotein metabolism and atherogenic lipoproteins during oral isotretinoin treatment. 1987 , 175 Suppl 1, 158-68		12
583	Apolipoprotein polymorphism and multifactorial hyperlipidaemia. 1988, 11 Suppl 1, 74-86		7
582	The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. 1988 , 79, 352-6		90
581	Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of LP(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. 1988 , 78, 41-6		181
580	Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. 1988 , 78, 47-50		102
579	Lipoprotein (a) and plasminogen are immunochemically related. 1988, 960, 91-7		91
578	Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord blood. 1988 , 177, 31-40		52
577	Immunochemical characterization and quantitation of lipoprotein (a) in baboons. Development of an assay depending on two antigenically distinct proteins. <i>Atherosclerosis</i> , 1988 , 73, 23-31	3.1	40
576	Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. 1988 , 1, 1070-3		218
575	Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. 1988 , 1, 1073-5		170
574	Lp(a) phenotyping by immunoblotting with polyclonal and monoclonal antibodies. 1988 , 8, 212-6		67
573	Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. 1988 , 77, 1238-44		232
572	Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. 1988 , 8, 851-7		128

571	Biochemistry and clinical significance of lipoprotein (a). 1988 , 25 (Pt 5), 499-503		14
570	Lipoprotein Abnormalities in Chronic Haemodialysis Patients. 1988,		
569	Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it <i>EMBO Journal</i> , 1989 , 8, 4035-4040	13	79
568	Apoprotein Measurements and Their Clinical Application. 1989 , 9, 137-152		35
567	Chapter 4. Laboratory Measurement of Plasma Lipids and Lipoproteins. 1989 , 79-112		
566	Chapter 8. The Dyslipoproteinemias of Diabetes Mellitus. 1989 , 173-206		1
565	Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin 1989 , 35, 2121-2123		124
564	Plasma lipoprotein(a) and the Friedewald formula 1989 , 35, 2156-2157		4
563	Interference of macro-creatine kinase in determination of CK-MB in serum with the Kodak Ektachem 1989 , 35, 2155-2156		1
562	Safe, easy removal of Cobas Bio sample cups 1989 , 35, 2156-2156		
561	HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. 1989 , 80, 1313-9		285
560	The mysteries of lipoprotein(a). 1989 , 246, 904-10		1103
559	Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. 1989 , 9, 579-92		398
558	Plasminogen polymorphism in swine. 1989 , 93, 325-31		
557	Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. 1989 , 19, 235-40		97
556	Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. 1989 , 226, 271-6		314
555	Apolipoproteins: Biochemistry, methods and clinical significance. 1989 , 17, 63-68		1
554	Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia. 1989 , 37, 545-50		16

553	The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. 1989 , 81, 149-52	68
55 ²	Lipoprotein(a) in nonhuman primates. Presence and characteristics of Lp(a) immunoreactive materials using anti-human Lp(a) serum. <i>Atherosclerosis</i> , 1989 , 78, 81-5	. 29
551	Transient changes of serum lipoprotein(a) as an acute phase protein. <i>Atherosclerosis</i> , 1989 , 78, 145-50 3.1	283
550	Production of lipoprotein(a) by primary baboon hepatocytes. 1989 , 1003, 30-5	35
549	A rapid electrophoretic method for the detection of serum Lp(a) lipoprotein. 1989 , 185, 147-55	15
548	Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans?. 1990 , 11 Suppl E, 184-9	26
547	Apolipoprotein Assays: Standardization and Quality Control. 1990 , 50, 58-65	12
546	Interaction of lipoprotein(a) with fibronectin and its potential role in atherogenesis. 1990 , 11 Suppl E, 190-5	18
545	Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. 1990 , 7, 736-43	25
544	Serum Lp(a) lipoprotein concentrations of Japanese patients with coronary heart disease. 1990 , 162, 261-7	3
543	Variation in the size of human apolipoprotein(a) is due to a hypervariable region in the gene. 1990 , 84, 563-7	38
542	Incidence of Lp(a) Lipoprotein among Populations. 1990 , 151-173	27
541	Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. 1990, 36, 20-23	340
540	The unique lipoprotein(a): properties and immunochemical measurement. 1990 , 36, 2019-2026	112
539	A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). 1990 , 36, 192-197	46
538	Lipoprotein(a). A unique risk factor for atherothrombotic disease. 1990 , 10, 672-9	256
537	Association of DNA polymorphism at the apolipoprotein B gene locus with coronary heart disease and serum very low density lipoprotein levels. 1990 , 10, 17-24	77
536	Lipoprotein(a), fibrin binding, and plasminogen activation. 1990 , 10, 240-5	390

535	Inborn Metabolic Diseases. 1990 ,		3
534	Cholesterol and coronary heart disease. 1990 , 199, 17-24		2
533	Serum lipids, lipoproteins and apolipoproteins in black patients with angiographically defined coronary artery disease. 1990 , 43, 425-32		12
532	A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas. 1990 , 58, 213-20		9
531	Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). <i>Atherosclerosis</i> , 1990 , 84, 173-81	3.1	117
530	Alterations of lipoprotein(a) in patients with diabetic nephropathy. <i>Atherosclerosis</i> , 1990 , 83, 99-100	3.1	52
529	Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. <i>Atherosclerosis</i> , 1990 , 85, 1-14	3.1	196
528	Does electrophoresis reliably screen for high serum lipoprotein Lp(a)?. 1990 , 188, 71-7		9
527	The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. 1990 , 188, 119-27		27
526	Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels. 1990 , 195, 9-15		19
525	Immunochemical determination of lipoprotein Lp(a): comparison of Laurell electrophoresis and ELISA. 1990 , 188, 187-92		18
524	Lipoprotein(a) enhances plasma clot lysis in vitro. 1990 , 267, 131-4		17
523	Plasma lipoprotein distribution of apolipoprotein(a) in the fed and fasted states. <i>Atherosclerosis</i> , 1991 , 90, 59-66	3.1	39
522	Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. <i>Atherosclerosis</i> , 1991 , 90, 95-7	3.1	60
521	Lp(a) lipoprotein in patients with arterial insufficiency of the lower extremities. 1991 , 5, 277-82		13
520	[The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]. 1991 , 12, 192-7		1
519	Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. 1991 , 30, 6671-7		73
518	Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. 1991 , 1081, 65-74		122

517	Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. 1991 , 204, 291-300		38
516	The effect of n-3 polyunsaturated fatty acids on Lp(a). 1991 , 198, 271-7		34
515	Lp(a) interactions. 1991 , 30, 195-203		9
514	Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. <i>Atherosclerosis</i> , 1991 , 89, 59-67	3.1	300
513	Does lipoprotein(a) (Lp(a)) complete with plasminogen in human atherosclerotic lesions and thrombi?. <i>Atherosclerosis</i> , 1991 , 89, 127-36	3.1	35
512	Effects of dietary fish oil supplementation on platelet aggregability and platelet membrane fluidity in normolipemic subjects with and without high plasma Lp(a) concentrations. <i>Atherosclerosis</i> , 1991 , 88, 193-201	3.1	36
511	Lipoprotein (a): The link between impaired fibrinolysis and atherosclerosis. 1991, 5, 135-143		50
510	Modified immunoblotting technique for phenotyping lipoprotein(a). 1991 , 37, 576-578		12
509	Seminars in thrombosis, thrombolysis, and vascular biology. Part 2: Coagulation and thrombosis. 1991 , 78, 257-66		5
508	A comparison of commercial kits for the measurement of lipoprotein(a). 1991 , 28 (Pt 4), 359-64		22
507	Clinical value of apolipoprotein measurement. 1991 , 28 (Pt 5), 427-37		19
506	Abnormalities of cholesterol metabolism in diabetes. 1991 , 50, 583-9		9
505	Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates. 1991 , 274 (Pt 2), 491-6		15
504	Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. 1991 , 67, 1349-53		28
503	Lipoprotein(a): nonhuman primate models. 1991 , 26, 679-83		22
502	Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. 1991 , 11, 247-53		88
501	Elevation of factor VII activity and mass in coronary artery disease of varying severity. 1991 , 14, 731-6		41
500	Apolipoprotein (a) levels in type 1 and type 2 diabetes mellitus. 1991 , 28, 158-61		11

499	Serum lipoprotein (a) levels in men with peripheral vascular disease. 1991, 42, 659-64		6
498	Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis?. 1991 , 11, 1772-7		30
497	Lipoprotein (a) concentrations as risk indicators for atherosclerosis. 1991 , 66, 1054-6		34
496	Inverse relationship between serum Lp(a) levels and first-phase insulin secretion. 1992 , 41, 1341-5		21
495	Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group. 1992 , 12, 1346-52		63
494	Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. 1992 , 12, 895-901		64
493	Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. 1992 , 288 (Pt 1), 101-7		49
492	Lp(a) levels in patients undergoing aorto-coronary bypass surgery. 1992 , 13, 1405-9		13
491	Serum lipoprotein(a) levels in racially different populations. 1992, 136, 441-9		61
490	Lipoprotein(a): A New Risk Factor for Vascular Disease. 1992 , 5, 84-99		1
			-
489	The effect of alcohol withdrawal on serum concentrations of Lp(a), apolipoproteins A-1 and B, and lipids. 1992 , 16, 895-8		35
489			
	lipids. 1992 , 16, 895-8 Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. 1992 ,	3.1	35
488	Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. 1992, 166, 1182-1190 Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary	3.1	35 88
488	Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. 1992, 166, 1182-1190 Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. <i>Atherosclerosis</i> , 1992, 94, 241-8		35 88 21
488 487 486	Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. 1992, 166, 1182-1190 Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. <i>Atherosclerosis</i> , 1992, 94, 241-8 Lipoprotein(a) at birth, in blacks and whites. <i>Atherosclerosis</i> , 1992, 92, 123-9		35 88 21 46
488 487 486 485	Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. 1992, 166, 1182-1190 Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. <i>Atherosclerosis</i> , 1992, 94, 241-8 Lipoprotein(a) at birth, in blacks and whites. <i>Atherosclerosis</i> , 1992, 92, 123-9 On the role of coagulation and fibrinolysis in atherosclerosis. 1992, 2, 427-38 Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with		35 88 21 46 62

481	A simple, sensitive technique for classification of apolipoprotein(a) isoforms by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. 1992 , 207, 215-25	12
480	The variation of serum lipoprotein (a) during surgical operations. 1992 , 212, 149-51	8
479	Standardization of Lp(a) assays. 1992 , 211, 191-4	16
478	Effect of Sample Storage on the Assay of Lipoprotein(a) by Commercially Available Radial Immunodiffusion and Enzyme-Linked Immunosorbent Assay Kits. 1992 , 38, 550-553	47
477	Performance of Proficiency Survey Samples in Two Immunoradiometric Assays of Human Growth Hormone and Comparison with Patients & Samples. 1992 , 38, 553-557	12
476	Does Serum Lipoprotein(a) Concentration Predict Restenosis After Percutaneous Transluminal Coronary Angioplasty?. 1992 , 211-216	
475	Lp(a) Lipoprotein: An Important Genetic Risk Factor for Atherosclerosis. 1992 , 14, 189-207	5
474	Lipid pattern, apolipoproteins A1 and B and lipoprotein (a) in type 1 diabetic patients with microalbuminuria. 1992 , 29, 246-249	2
473	Lp(a) and the risk of coronary heart disease. 1992 , 8 Suppl 1, 33-5	9
472	A structural assessment of the apo[a] protein of human lipoprotein[a]. 1992 , 12, 188-99	60
471	Comparison of three methods of isolating lipoprotein (a) from human blood plasma. 1992 , 113, 345-348	1
470	Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. 1992 , 22, 173-8	46
469	Lipoprotein [Lp(a)] and peripheral vascular disease. 1992 , 232, 349-52	54
468	Automated latex nephelometric immunoassay for the measurement of serum lipoprotein (a). 1993 , 7, 105-10	8
467	Immunoquantification of lipoprotein(a): comparison of nephelometry with electroimmunodiffusion. 1993 , 7, 256-62	11
466	Apolipoprotein (a): a comparison of isoforms identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or by sodium dodecyl sulfate-agarose gel electrophoresis. 1993 , 14, 1038-41	7
465	Frequent occurrence of familial aggregations of high lipoprotein(a) levels associated with small apolipoprotein(a) isoforms. 1993 , 92, 545-8	3
464	Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. 1993 , 23, 580-4	32

463	Lipoprotein (a): a risk factor for peripheral vascular disease. 1993 , 7, 446-51		33
462	Molecular definition of the extreme size polymorphism in apolipoprotein(a). 1993 , 2, 933-40		2 90
461	Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. 1993 , 42, 236-46		80
460	Alteration of lipoprotein(a) concentration with glycemic control in non-insulin-dependent diabetic subjects without diabetic complications. 1993 , 42, 1323-6		21
459	The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. 1993 , 223, 73-82		34
458	Lipoprotein(a) serum concentration in familial combined hyperlipidemia. 1993 , 223, 121-7		7
457	Determination of lipoprotein(a): enzyme immunoassay and immunoradiometric assay compared. 1993 , 214, 153-63		25
456	Comparison of lipoprotein(a) assay methods in serum and in a plasminogen-free fraction. 1993 , 218, 83-95		7
455	Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. 1993, 325, 271-5		67
454	Atherosclerosis in a rhesus monkey with genetic hypercholesterolemia and elevated plasma Lp(a). <i>Atherosclerosis</i> , 1993 , 99, 165-74	3.1	21
453	The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. <i>Atherosclerosis</i> , 1993 , 101, 61-8	3.1	78
452	Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 1993 , 101, 69-77	3.1	30
451	Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. <i>Atherosclerosis</i> , 1993 , 101, 203-11	3.1	49
450	Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. <i>Atherosclerosis</i> , 1993 , 98, 139-51	3.1	45
449	Lp(a) levels and antiestrogen antibodies in women with and without thrombosis in the course of oral contraception. <i>Atherosclerosis</i> , 1993 , 100, 183-8	3.1	4
448	Effects of lipoprotein(a) on in vitro lysis of whole blood thrombi from healthy volunteers. 1993 , 69, 47	9-87	13
447	Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. 1993 , 32, 4628-33		88
446	Acrylodan can label amino as well as sulfhydryl groups: results with low-density lipoprotein, lipoprotein[a], and lipid-free proteins. 1993 , 32, 9215-20		14

445	Elevated lipoprotein (a) levels in primary nephrotic syndrome. 1993 , 22, 808-13	33
444	Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. 1993 , 22, 226-32	26
443	Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women. 1993 , 13, 675-9	32
442	The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. 1993 , 13, 1558-66	61
441	Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. 1993 , 13, 1429-40	22
440	Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease. 1993 , 69, 26-30	8
439	Determination of lipoprotein(a): evaluation of three methods. 1993, 31, 295-302	6
438	Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. 1993 , 88, 935-40	65
437	A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction. 1993 , 270, 2195	263
436	Interaction of Lp(a) and of apo(a) with liver cells. 1993 , 13, 1101-9	31
436	Interaction of Lp(a) and of apo(a) with liver cells. 1993, 13, 1101-9 TECHNICAL NOTE. 1993, 31,	31
		31
435	TECHNICAL NOTE. 1993 , 31,	2 3
435	TECHNICAL NOTE. 1993 , 31, Pre-analytical, analytical and biological sources of variation of lipoprotein(a). 1993 , 31, 23-8 Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary	2
435 434 433	TECHNICAL NOTE. 1993, 31, Pre-analytical, analytical and biological sources of variation of lipoprotein(a). 1993, 31, 23-8 Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease. 1993, 169, 299-307 Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on	2
435 434 433 432	TECHNICAL NOTE. 1993, 31, Pre-analytical, analytical and biological sources of variation of lipoprotein(a). 1993, 31, 23-8 Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease. 1993, 169, 299-307 Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels. 1993, 10, 427-30 The effect of microalbuminuria on glycaemic control, serum lipids and haemostasis parameters in	2 3 22
435 434 433 432 431	TECHNICAL NOTE. 1993, 31, Pre-analytical, analytical and biological sources of variation of lipoprotein(a). 1993, 31, 23-8 Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease. 1993, 169, 299-307 Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels. 1993, 10, 427-30 The effect of microalbuminuria on glycaemic control, serum lipids and haemostasis parameters in non-insulin-dependent diabetes mellitus. 1993, 30 (Pt 5), 439-44 Relation of lipoprotein(a) in 11- to 19-year-old adolescents to parental cardiovascular heart disease.	2 3 22 11

427	Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy. 1994 , 1, 37-40	8
426	Effects of LDL-apheresis on serum lipoprotein (a), C4b binding protein, protein C, protein S, and complement components. 1994 , 1, 103-7	5
425	Effects of cigarette smoking on plasma lipids, apolipoproteins, and lipoprotein(a) in healthy subjects. 1994 , 40, 1350-1351	9
424	Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. 1994 , 14, 1399-404	66
423	Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. 1994 , 14, 1561-8	36
422	Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. 1994 , 14, 1272-83	36
421	Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. 1994 , 14, 1405-11	69
420	Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. 1994 , 14, 1609-16	23
419	SHORT COMMUNICATION. 1994 , 32,	
418	The behaviour of lipoprotein(a) in patients with various diseases. 1994 , 54, 559-62	29
418 417	The behaviour of lipoprotein(a) in patients with various diseases. 1994 , 54, 559-62 Nonrenal complications of the nephrotic syndrome. 1994 , 45, 201-10	29
		·
417	Nonrenal complications of the nephrotic syndrome. 1994 , 45, 201-10 Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral	20
417 416	Nonrenal complications of the nephrotic syndrome. 1994 , 45, 201-10 Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men. 1994 , 154, 801 Immunoluminometric assays for the quantification of apolipoproteins A-I, B, C-II, apolipoprotein(a)	20 69
417 416 415	Nonrenal complications of the nephrotic syndrome. 1994 , 45, 201-10 Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men. 1994 , 154, 801 Immunoluminometric assays for the quantification of apolipoproteins A-I, B, C-II, apolipoprotein(a) and lipoprotein(a). 1994 , 32, 127-35 A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and	20 69 2
417 416 415 414	Nonrenal complications of the nephrotic syndrome. 1994 , 45, 201-10 Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men. 1994 , 154, 801 Immunoluminometric assays for the quantification of apolipoproteins A-I, B, C-II, apolipoprotein(a) and lipoprotein(a). 1994 , 32, 127-35 A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. 1994 , 90, 1688-95 Correlation between plasma lipoprotein Lp(a) and sex hormone concentrations: a cross-sectional	20 69 2 206
417 416 415 414 413	Nonrenal complications of the nephrotic syndrome. 1994, 45, 201-10 Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men. 1994, 154, 801 Immunoluminometric assays for the quantification of apolipoproteins A-I, B, C-II, apolipoprotein(a) and lipoprotein(a). 1994, 32, 127-35 A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. 1994, 90, 1688-95 Correlation between plasma lipoprotein Lp(a) and sex hormone concentrations: a cross-sectional study in healthy males. 1994, 26, 602-8 Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gftingen Risk Incidence and Prevalence Study	20 69 2 206

409	Primary structure of apoB-100. 1994 , 67-68, 99-104	16
408	Triglyceride-rich lipoprotein interactions with Lp(a). 1994 , 67-68, 105-13	14
407	Effect of lipoprotein(a) on lipid metabolism of cultured human intimal aortic cells. 1994 , 67-68, 161-6	2
406	Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein(a). 1994 , 67-68, 207-21	23
405	Lipoprotein(a) as a risk factor for preclinical atherosclerotic disease in a biracial cohort: the Atherosclerosis Risk in Communities (ARIC) Study. 1994 , 67-68, 405-10	22
404	Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of the carotid arteries. 1994 , 67-68, 429-34	9
403	Structure and possible biological roles of Lp(a). 1994 , 27, 151-62	9
402	Elevated endothelin levels in patients with hyperlipoproteinemia. 1994 , 72, 580-4	24
401	Plasma lipids and lipoproteins and essential hypertension. 1994 , 72, 944-50	22
400	Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data. 1994 , 67-68, 323-30	34
399	Lipoprotein(a) and coronary heart disease. 1994 , 67-68, 389-98	15
398	Discrepancies between lipoprotein(a) concentrations in icteric sera measured by immunonephelometry and electroimmunodiffusion. 1994 , 27, 7-11	3
397	Lipoprotein levels in newborns and adolescents. 1994 , 27, 305-6	12
396	Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. 1994 , 73, 742-6	36
395	Serum lipoprotein changes after prolonged intralipid infusion in malnourished haemodialysis patients. 1994 , 13, 111-5	9
394	Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase: no prediction of efficacy but inverse correlation with plasminogen activation in non-patency. 1994 , 45, 109-13	10
393	Apo(a) expression in transgenic mice. 1994 , 714, 231-6	
392	Low-density lipoprotein activates the protease region of recombinant apo(a). 1994 , 1215, 170-5	3

391	Effect of storage of sera and apolipoprotein(a) phenotypes on detection of lipoprotein(a) by a new agarose gel. 1994 , 225, 195-201	3
390	A screening method for abnormally high lipoprotein(a) concentrations by agarose lipoprotein electrophoresis. 1994 , 230, 43-50	6
389	Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. 1994 , 224, 125-9	12
388	The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. 1994 , 8, 294-30) 3 40
387	Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis?. 1994, 31, 445-9	32
386	Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. <i>Atherosclerosis</i> , 1994 , 105, 1-7	49
385	Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. <i>Atherosclerosis</i> , 1994 , 106, 9-19	437
384	Lipids, lipoproteins and coronary heart disease in minority populations. <i>Atherosclerosis</i> , 1994 , 108 Suppl, S83-104	29
383	Effects of doxazosin on blood pressure and serum lipid levels in hypertensive patients. 1994 , 55, 843-850	
382	Lipoprotein(a) and risks of cardiovascular disease. 1994 , 4, 360-2	13
381	Distribution of Lipoprotein (a) and Relationships between its Level and Blood Chemical Findings in a Rural Area in Japan. 1994 , 4, 163-169	
380	Three types of "mid-band" lipoproteins in non-insulin-dependent diabetes mellitus: relation to metabolic abnormalities and vascular complications. 1994 , 173, 247-57	
379	Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. 1994 , 78, 99-115	52
378	Lipoprotein(a) and ischemic cerebrovascular disease in young adults. 1994 , 25, 74-8	90
377	Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). 1995 , 92, 10147-51	71
376	Lipoprotein (a) does not influence hyperfibrinolysis in patients with liver cirrhosis. 1995 , 9, 133-138	4
375	Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. 1995 , 76, 459-62	43
374	Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). 1995 , 76, 928-32	117

373	High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. 1995 , 25, 368-70	14
372	Lipoprotein(a): levels in a Swedish population in relation to other lipid parameters and in comparison with a male Sri Lankan population. 1995 , 28, 427-34	6
371	Enzyme immunoassay of lipoprotein(a). 1995 , 120, 1030-1033	8
370	La lp(a): intfEde son dosage et interprtation des rsultats. 1995 , 1995, 160-165	
369	Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein (a) size polymorphism. 1995 , 95, 275-82	32
368	An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. 1995 , 5, 225-9	7
367	Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. 1995 , 41, 731-738	30
366	Inhibitors for the in vitro assembly of Lp(a). 1995 , 15, 1774-80	38
365	Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study. 1995 , 15, 1549-55	42
364	Human Lp(a): regions in sequences of apoproteins similar to domains in signal transduction proteins. 1995 , 1, 440-8	1
363	Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. 1995 , 141, 815-21	62
362	Elevated levels of lipoprotein (a) in association with cerebrovascular saccular aneurysmal disease. 1995 , 37, 241-5	19
361	Comparison of a new immunoturbidometric assay of human serum lipoprotein (a) to the ELISA and the IRMA methods. 1995 , 55, 171-80	18
360	Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. 1995 , 74, 365-9	14
359	Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. 1995 , 54, 90-3	22
358	Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. 1995 , 270, 31151-7	79
357	Plasma Concentration of Lipoprotein(a) and the Risk of Future Stroke. 1995 , 273, 1269	70
356	Lipids and atherosclerosis. 1995 , 16, 509-710	10

(1996-1995)

355	Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). 1995 , 44, 1559-63	58
354	Serum lipoprotein(a) levels before and after subtotal thyroidectomy in subjects with hyperthyroidism. 1995 , 44, 4-7	10
353	Immunoturbidimetric determination of lipoprotein(a): improvement in the measurement of turbid and triglyceride-rich samples. 1995 , 235, 59-69	13
352	Whether, to what degree, and why lipoprotein(a) levels change over time. 1995 , 238, 11-9	12
351	Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. 1995 , 26, 1242-50	48
350	Thrombophilic factors in ischaemic and non-ischaemic idiopathic retinal vasculitis. 1995 , 9 (Pt 4), 507-12	9
349	Lipoprotein(a) plasma levels and apo(a) isoforms are not associated with longevity or disability in a sample of Italian octo-nonagenarians. Associazione Medica Sabin. 1995 , 7, 385-91	9
348	High levels of serum lipoprotein(a) in patients with ischemic heart disease with normal coronary angiogram and thromboangiitis obliterans. <i>Atherosclerosis</i> , 1995 , 112, 253-60	9
347	Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwana unique experience. <i>Atherosclerosis</i> , 1995 , 118, 285-95	50
346	Lipoprotein (a) and apolipoprotein A-1 and B in schoolchildren whose grandparents had coronary and cerebrovascular events: a preliminary study of 12-13 year old Japanese children. 1995 , 37, 582-7	10
345	Lipoprotein (a). 1995 , 9, 773-95	19
344	Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. 1995 , 26, 170-7	7
343	Thrombolysis with tissue plasminogen activator enhances serum lipoprotein(a) levels compared to streptokinase and conservative treatment in patients with acute myocardial infarction. 1996 , 10, 263-268	3
342	Serum lipoprotein(a) [Lp(a)] in alcoholic men: effect of withdrawal. 1996 , 13, 309-14	11
341	Plasma lipoprotein(a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay. 1996 , 253, 21-35	23
340	Lipoprotein(a) in health and disease. 1996 , 33, 495-543	72
339	Effects of growth hormone on serum lipids and lipoproteins: possible significance of increased peripheral conversion of thyroxine to triiodothyronine. 1996 , 45, 1016-20	9
338	Lipoprotein(a) in renal disease. 1996 , 27, 1-25	205

337	The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition. 1996 , 192, 224-32		11
336	Lipoprotein(a) and its correlates in Japanese and U.S. population samples. 1996 , 6, 324-30		7
335	Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. 1996 , 16, 471-8		79
334	Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. 1996 , 16, 648-55		20
333	Induction of hepatic uptake of lipoprotein(a) by cholesterol-derivatized cluster galactosides. 1996 , 16, 1552-8		4
332	Elevated serum Lp(a) concentration and the rare apo(a) phenotype in a patient with myocardial infarction. 1996 , 19, 758-9		1
331	Blood pressure, serum lipids, and fatty acids in populations on a lake-fish diet or on a vegetarian diet in Tanzania. 1996 , 31 Suppl, S309-12		21
330	Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. 1996 , 40, 265-70		34
329	The assembly of lipoprotein Lp(a). 1996 , 26, 109-14		32
328	Hyperlipoprotein(a)aemia in nephrotic syndrome. 1996 , 26, 316-21		13
327	Effect of Oral Estradiol on Lp(a) and Other Lipoproteins in Postmenopausal Women. 1996 , 156, 866		22
226			
326	The role of lipoprotein(a) in atherogenesis and thrombosis. 1996 , 47, 423-42		76
325	The role of lipoprotein(a) in atherogenesis and thrombosis. 1996 , 47, 423-42 Do gonadotropins influence serum lipoprotein(a) concentrations? Observations on children, adolescents and adults. 1996 , 34, 909-14		76
	Do gonadotropins influence serum lipoprotein(a) concentrations? Observations on children,		76 4
325	Do gonadotropins influence serum lipoprotein(a) concentrations? Observations on children, adolescents and adults. 1996 , 34, 909-14		
325 324	Do gonadotropins influence serum lipoprotein(a) concentrations? Observations on children, adolescents and adults. 1996 , 34, 909-14 Lifibrol: first member of a new class of lipid-lowering drugs?. 1997 , 6, 583-91 Transgenic mice expressing human ApoB95 and ApoB97. Evidence that sequences within the carboxyl-terminal portion of human apoB100 are important for the assembly of lipoprotein. 1997 ,	3.1	4
325 324 323	Do gonadotropins influence serum lipoprotein(a) concentrations? Observations on children, adolescents and adults. 1996, 34, 909-14 Lifibrol: first member of a new class of lipid-lowering drugs?. 1997, 6, 583-91 Transgenic mice expressing human ApoB95 and ApoB97. Evidence that sequences within the carboxyl-terminal portion of human apoB100 are important for the assembly of lipoprotein. 1997, 272, 23616-22 Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis, 1997,	3.1	4 35

319	Genetic determinants of atherosclerosis-related dyslipidemias and their clinical implications. 1997 , 257, 181-97	20
318	Lipoprotein (a) serum levels in patients with hepatocarcinoma. 1997 , 262, 53-60	11
317	The cardiovascular safety of triphasic contraceptive steroids. 1997 , 56, 157-63	2
316	Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels. 1997, 46, 355-8	2
315	Elevated serum lipoprotein(a) levels in young women with endometriosis. 1997 , 46, 735-9	23
314	Metabolic aspects of trans fatty acids. 1997 , 16, 229-37	35
313	Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. 1997 , 17, 2783-92	63
312	Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids. 1997 , 17, 1657-61	69
311	Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. 1997 , 43, 1891-1895	27
310	Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. 1997 , 14, 17-23	60
309	Urinary excretion of apo(a) fragments in NIDDM patients. 1997 , 40, 1455-60	10
308	Biogenesis of lipoprotein(a) in human and animal hepatocytes. 1997 , 18, 2677-81	3
307	Elevated levels of lipoprotein(a) in women with preeclampsia. 1998 , 178, 146-9	40
306	Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. 1998 , 54, 1344-50	24
305	Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. 1998 , 28, 447-52	25
304	Cemetery for lipoprotein (a): the kidney. 1998 , 28, 453-5	
303	Vascular risk factors and lipoprotein(a) levels in the differential diagnosis of dementias. 1998 , 26, 539-548	1
302	Growth hormone deficiency and cardiovascular risk. 1998 , 12, 199-216	31

301	Upregulated synthesis of both apolipoprotein A-I and apolipoprotein B in familial hyperalphalipoproteinemia and hyperbetalipoproteinemia. 1998 , 47, 1160-6	5
300	Urinary apolipoprotein (a) excretion in patients with proteinuria. 1998 , 30, 497-502	11
299	Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells. 1998, 37, 5417-25	39
298	Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57> Asn mutation in kringle IV-10 is associated with poor fibrin binding. 1998 , 37, 7213-23	14
297	Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. 1998 , 136, 965-71	21
296	Influence of lipoprotein(a) plasma concentration on neointimal growth in a monkey model of vascular injury. <i>Atherosclerosis</i> , 1998 , 139, 137-45	2
295	Long-term variability of serum lipoprotein(a) concentrations in healthy fertile women. 1998, 36, 317-21	9
294	Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. 1998 , 98, 1172-7	18
293	Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. 1998 , 97, 721-8	92
292	Atherosclerosis: coagulation and fibrinolysis. 1998 , 24, 255-60	27
291	The Relationship of Various Factors in the Pathogenesis of Atherosclerosis. 1998 , 4, 105-110	9
290	Apo(a) phenotypes and lp(a) concentrations in renal transplant patients. 1998, 80, 183-7	6
289	International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. 1998 , 44, 1629-1640	60
288	Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. 1998 , 44, 2301-2306	154
287	Changes in Serum Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Positive Breast Cancer Treated with Tamoxifen. 1998 , 84, 687-690	15
286	Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children. 1999 , 153, 57-62	8
285	The levels of lipids, lipoproteins and apolipoproteins in healthy people in the central region of the Black Sea. 1999 , 40, 427-34	6
284	Vergleich einer kinetischen Nephelometrie mit einem immunoradiometrischen Assay f∐die Bestimmung von Lipoprotein(a) 1999 , 23, 85-90	

(2000-1999)

283	Project for the Measurement of Lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a). 1999 , 37, 949-58		47
282	Lipoprotein(a), apolipoprotein A-I and B serum levels in young families from Tallinn, Estonia. Relationships with other cardiovascular risk factors and nationality. 1999 , 59, 179-89		4
281	Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?. 1999 , 7, 277-85		17
280	Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels. 1999 , 133, 237-44		10
279	The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy. 1999 , 9, 165-73		25
278	Effect of tranexamic acid and delta-aminovaleric acid on lipoprotein(a) metabolism in transgenic mice. 1999 , 1438, 99-110		17
277	Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. 1999 , 68, 23-9		37
276	Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitus patients. 1999 , 48, 369-72		7
275	Correlates of lipoprotein(a) levels in a biracial cohort of young girls: the NHLBI Growth and Health Study. 1999 , 135, 169-76		13
274	Effects of exercise on lipoprotein(a). 1999 , 28, 11-24		26
273	Effects of misoprostol on lipoprotein (a) levels of ovariectomized rats. 1999, 72, 518-21		7
272	Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. <i>Atherosclerosis</i> , 1999 , 144, 323-33	3.1	48
271	The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: differences between men and women. <i>Atherosclerosis</i> , 1999 ,	3.1	18
	144, 221-8		
270	144, 221-8 Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance. 1999 , 38, 1990-8		19
270 269	Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes,		19
	Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance. 1999 , 38, 1990-8		
269	Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance. 1999 , 38, 1990-8 Inflammation nutritional state and outcome in end stage renal disease. 1999 , 25, 242-50 Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral		31

265	Cardiovascular risk markers in hypothalamic amenorrhoea. 2000 , 53, 359-66	1
264	[Genetic risk factors for myocardial infarct]. 2000 , 25, 7-14	4
263	Hemodialysis vascular access thrombosis and lipoprotein(a). 2000 , 1, 84-7	1
262	Lipoprotein(a): what © in a measure?. 2000 , 37 (Pt 5), 571-80	6
261	Atherosclerosis. 2000,	1
2 60	Production and characterization of monoclonal antibodies directed to the kringle V and protease domains of human apolipoprotein(a). 2000 , 19, 435-44	1
259	The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. 2000 , 21, 639-46	27
258	Apo(a)-kringle IV-type 6: expression in Escherichia coli, purification and in vitro refolding. 2000 , 13, 661-6	9
257	10 Lipoprotein(a) Quantitation. 2001 , 52, 113-22	1
256	High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. 2000 , 20, 2619-24	140
256 255		140
	African American and white men. 2000 , 20, 2619-24 Premenopausal black women are uniquely at risk for coronary heart disease compared to white	
255	African American and white men. 2000, 20, 2619-24 Premenopausal black women are uniquely at risk for coronary heart disease compared to white women. 2000, 3, 105-117 Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and	3
² 55	African American and white men. 2000, 20, 2619-24 Premenopausal black women are uniquely at risk for coronary heart disease compared to white women. 2000, 3, 105-117 Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. 2000, 139, 164-73 Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in	3 64
²⁵⁵ ²⁵⁴ ²⁵³	African American and white men. 2000, 20, 2619-24 Premenopausal black women are uniquely at risk for coronary heart disease compared to white women. 2000, 3, 105-117 Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. 2000, 139, 164-73 Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. 2000, 36, 826-36 LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide	3 64 48
255 254 253 252	African American and white men. 2000, 20, 2619-24 Premenopausal black women are uniquely at risk for coronary heart disease compared to white women. 2000, 3, 105-117 Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. 2000, 139, 164-73 Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. 2000, 36, 826-36 LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis, 2000, 151, 551-7 Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in	3 64 48 41
255 254 253 252 251	African American and white men. 2000, 20, 2619-24 Premenopausal black women are uniquely at risk for coronary heart disease compared to white women. 2000, 3, 105-117 Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. 2000, 139, 164-73 Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. 2000, 36, 826-36 LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis, 2000, 151, 551-7 Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis, 2001, 157, 241-9 Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle	3 64 48 41 42

247	Fluorescence-based, Nonradioactive Method for Efficient Detection of the Pentanucleotide Repeat (TTTTA)n Polymorphism in the Apolipoprotein(a) Gene. 2001 , 47, 1758-1762	4
246	Levels of lipoprotein (a) in pulmonary arterial hypertension. 2001 , 11, 25-9	3
245	. 2001 , 8, 311-317	20
244	Hormone Replacement Therapy in Primary and Secondary Prevention of Coronary Artery Disease: Cardiologist and Geriatric Specialist Perspectives. 2001 , 23, 409-416	
243	Basal and post-methionine serum homocysteine and lipoprotein abnormalities in patients with chronic liver disease. 2001 , 49, 325-9	11
242	Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype. 2001 , 77, 283-6	4
241	Coronary heart disease in African Americans. 2001 , 3, 97-108	116
240	Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo. 2001 , 8, 425-30	16
239	Impact of apolipoprotein(a) on in vitro angiogenesis. 2001 , 21, 433-8	32
238	Die Differentialdiagnostik von Fettstoffwechselstfungen unter besonderer Berflksichtigung methodischer Aspekte. Differential Diagnostics of Disorders in Lipid Metabolism with Special Consideration of Methodical Aspects. 2001 , 25, 16-22	
237	The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia. 2002, 30, 271-81	4
236	Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. 2002 , 22, 494-506	13
235	Relation of small artery compliance and lipoprotein (a) in patients with atherosclerosis. 2002, 15, 980-5	7
234	Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients. 2002 , 56, 221-7	10
233	Lipoprotein (a) in patients with aortic aneurysmal disease. 2002 , 36, 25-30	28
232	Relationship of renal function to homocysteine and lipoprotein(a) levels: the frequency of the combination of both risk factors in chronic renal impairment. 2002 , 40, 916-23	23
231	Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. 2002 , 252, 27-35	33
230	Influence of systemic factors on pre-existing intimal hyperplasia and their effect on the outcome of infrainguinal arterial reconstruction with vein. 1999 , 86, 1441-7	14

229	Hormonal influences on lipoprotein(a) metabolism. 2002 , 4, 156-65	2
228	Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. 2003 , 36, 129-34	11
227	Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus. 2003 , 36, 545-51	10
226	Factors contributing to variation in lipoprotein (a) in Melbourne Anglo-Celtic population. 2003, 57, 447-54	6
225	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. 2003 , 328, 91-7	1
224		
223	Levels of lipoprotein(a) in normal and compromised pregnancy. 2003, 31, 23-8	8
222	The impact of hyperhomocysteinemia as a cardiovascular risk factor in the prediction of coronary heart disease. 2003 , 41, 1513-7	10
221	Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. 2003 , 24, 198-208	54
220	Application of virtual reality in volumetric cellular visualization. 2004 ,	Ο
219	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). 2004 , 38, 253-9	117
219	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). 2004 , 38, 253-9	117
219	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). 2004 , 38, 253-9 Lipoprotein(a): an elusive cardiovascular risk factor. 2004 , 24, 2219-26 Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2	117 175
219 218 217	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). 2004, 38, 253-9 Lipoprotein(a): an elusive cardiovascular risk factor. 2004, 24, 2219-26 Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. 2004, 27, 517-21 Lipoprotein parameters in relation to other risk factors of atherosclerosis in adults and newborns:	117 175 42
219 218 217 216	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). 2004, 38, 253-9 Lipoprotein(a): an elusive cardiovascular risk factor. 2004, 24, 2219-26 Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. 2004, 27, 517-21 Lipoprotein parameters in relation to other risk factors of atherosclerosis in adults and newborns: Tallinn Young Family Study. 2004, 64, 245-53 Relationship between plasma lipoprotein (a), apolipoprotein (a) phenotypes, and other coronary	117 175 42 13
219 218 217 216 215	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). 2004, 38, 253-9 Lipoprotein(a): an elusive cardiovascular risk factor. 2004, 24, 2219-26 Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. 2004, 27, 517-21 Lipoprotein parameters in relation to other risk factors of atherosclerosis in adults and newborns: Tallinn Young Family Study. 2004, 64, 245-53 Relationship between plasma lipoprotein (a), apolipoprotein (a) phenotypes, and other coronary heart disease risk factors in a Melbourne South Asian population. 2004, 37, 305-11 Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without	117 175 42 13

211	Review of the Derivation and Applicability of Selected Biochemical Indicators of Nutritional Status as Predictors of Chronic Disease in the Elderly. 2004 , 19, 200-214	1
210	Diet and Plasma Lipoproteins in Elderly With and Without Cardiovascular Disease. 2004, 19, 215-225	
209	High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. 2005 , 16, 1141-8	197
208	Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. 2005 , 28, 1718-23	23
207	Serum lipid and apolipoprotein profiles in newborns and six-year-old children: the Tallinn Young Family Study. 2005 , 65, 541-50	6
206	Lipoprotein(a): a unique risk factor for cardiovascular disease. 2006 , 26, 751-72	77
205	Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk. 2006 , 21, 129-33	11
204	Procoagulant properties of atherosclerotic aortas. 1995 , 748, 185-92; discussion 192-3	8
203	Serum lipoprotein (a) levels in patients with diabetic foot lesions. 2006, 71, 119-23	4
202	Predictors of coronary artery disease in the Lebanese population. 2006, 117, 631-7	19
201	Apolipoprotein A-V gene polymorphism -1131T>C and Alzheimer@ disease. 2006 , 10, 365-9	5
200	Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. 2006 , 296, 1363-70	149
199	Electroelution of lipoprotein(a) [Lp(a)] from native polyacrylamide gels: a new, simple method to purify Lp(a). 2006 , 68, 43-53	4
198	Aortic valve calcification in systemic lupus erythematosus. 2006 , 15, 873-6	8
197	Determinants of risk factors of atherosclerosis in the postinfarction period: the Tallinn MI study. 2006 , 66, 191-9	8
196	Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. <i>Journal of Lipid Research</i> , 2006 , 47, 982-9	22
195	Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. 2007 , 26, 39-50	112
194	Lipoprotein(a) 卧truktur, Epidemiologie und Funktion / Lipoprotein(a) 卧tructure, epidemiology and function. 2007 , 31, 109-124	O

193	Estrogen Therapy for the Lipid Abnormalities of Women on Dialysis. 2007 , 7, 149-150	
192	Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis, 2007 , 193, 269-76	13
191	Lipoprotein (a) and the kidney. 2007 , 3, 139-142	
190	Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. 2007 , 67, 129-34	54
189	Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. 2007 , 37, 180-6	11
188	ApoB-100 and ApoB/ApoA-1 ratio in children and adolescents from families with very early myocardial infarction. 2007 , 95, 810-813	1
187	Comparison of Lipoprotein(a) levels between elderly and middle-aged men with coronary artery disease. 2007 , 1100, 179-84	8
186	Markers of Chlamydia pneumoniae and human cytomegalovirus infection in patients with chronic peripheral vascular disease and their relation to inflammation, endothelial dysfunction and changes in lipid metabolism. 2008 , 53, 551-7	3
185	Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. 1997, 52, 262-71	23
184	Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. 1997 , 52, 281-92	54
183	Studies on the structure and function of the apolipoprotein(a) gene. 1994 , 46, 34-41	5
182	Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction. 1994 , 46, 410-6	22
181	Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. 2008 , 57, 791-5	14
180	Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. 1991 , 15, 136-40	27
179	Lp(a) lipoprotein in cerebrovascular disease and dementia. 1987 , 41, 743-8	
178	Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. 2009 , 6, 229-39	167
177	Antiphospholipid antibodies and lipoprotein(a) in obese children. 2009 , 98, 703-7	
176	Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. 2009 , 48, 379-87	23

175	Androgenic anabolic steroid abuse and the cardiovascular system. 2010 , 411-57	69
174	Enigmatic role of lipoprotein(a) in cardiovascular disease. 2010 , 3, 327-32	9
173	Lipoprotein (a) and Apolipoprotein (a) Isoforms in Patients with Acute Myocardial Infarction. 2010 , 1, 71-76	
172	C-ràctive protîne ultrasensible et facteurs de risque cardiovasculaire dans une population tunisienne. 2011 , 26, 107-112	
171	Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2011 , 216, 426-32	44
170	Increased Lipoprotein (a) concentrations in patients with chronic venous leg ulcers: a study on patients with or without postthrombotic syndrome. 2011 , 19, 168-72	4
169	Lipoprotein(a): Cellular Effects and Molecular Mechanisms. 2012, 2012, 923289	36
168	FGF19 signaling cascade suppresses APOA gene expression. 2012 , 32, 1220-7	33
167	Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. <i>Journal of Lipid Research</i> , 2012 , 53, 2405-12	42
166	Association between Lipoprotein (a) level on admission and the incidence of subsequent cardiovascular events in patients with acute coronary syndrome. 2012 , 158, 464-6	11
165	Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. 2012 , 1821, 1443-52	75
164	Lipoprotein (a) [An Overview. 2012 ,	1
163	When should we measure lipoprotein (a)?. 2013, 34, 3268-76	53
162	Lipoprotein (a): structure, pathophysiology and clinical implications. 2014 , 103, 76-84	44
161	Lipoprotein(a) mass: a massively misunderstood metric. 2014 , 8, 550-553	36
160	Lipoprotein(a): Structure, Metabolism, and Pathophysiology. 2014 , 141-155	
159	Lipoprotein(a) als wichtiger Risikofaktor ffl Gefflerschl\(\text{lse}\). Bericht \(\text{ber}\) eine beidseitige nicht-entz\(\text{ld}\) diche anteriore isch\(\text{lhi}\) ische Optikusneuropathie mit erfolgreicher Behandlung eines Auges und Langzeitbeobachtung. 2014 , 28, 136-141	
158	Lipoprotein(a): when to measure, how to treat?. 2015 , 39,	1

Lipoprotein(a): wann messen, wie behandeln?. 2015, 39,

156	Differenzierung der Indikation zur Lipoproteinapherese bei erhlitem Lp(a) durch unterschiedliche Messmethoden. 2015 , 15, 36-38		5
155	Lipoprotein(a) 🖪 Hallmark in Atherosclerosis and Cardiovascular Diseases. 2015,		
154	Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2015 , 242, 226-9	3.1	22
153	Lipoprotein(a). 2015 , 25-55		2
152	Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. 2015 , 278, 166-73		69
151	Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. 2016 , 31, 1110-1119		12
150	Structure, function, and genetics of lipoprotein (a). <i>Journal of Lipid Research</i> , 2016 , 57, 1339-59	6.3	204
149	Live donor study - implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a. 2016 , 21, 901-4		6
148	Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. <i>Journal of Lipid Research</i> , 2016 , 57, 1953-1975	6.3	242
147	Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. 2016 , 36, 2239-2245		75
146	Hohe Lipoprotein(a)-Werte als schwerwiegender Risikofaktor ffldie koronare Herzkrankheit 🛭 Darstellung von 6 Kasuistiken. 2016 , 11, 213-217		
145	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. <i>Journal of Lipid Research</i> , 2016 , 57, 697-705	6.3	22
144	Lipoprotein (a): impact by ethnicity and environmental and medical conditions. <i>Journal of Lipid Research</i> , 2016 , 57, 1111-25	6.3	87
143	Lipoprotein (a) measurements for clinical application. <i>Journal of Lipid Research</i> , 2016 , 57, 526-37	6.3	149
142	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. 2017 , 69, 692-711		396
141	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. 2017 , 5, 534-543		69
140	Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke. 2017, 48, 36-42		12

139	Lipoprotein (a): a historical appraisal. Journal of Lipid Research, 2017, 58, 1-14	6.3	31
138	Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. <i>Atherosclerosis</i> , 2018 , 274, 16-22	3.1	23
137	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. 2018 , 392, 1311-1320		208
136	Treating Lipid Disorders in Athletes. 2018 , 25-48		
135	Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction. 2018 , 484, 232-236		8
134	Lp(a): Addressing a Target for Cardiovascular Disease Prevention. 2019 , 21, 102		10
133	Lipoprotein(a) and coronary artery disease in Chinese postmenopausal female patients: a large cross-sectional cohort study. 2019 , 95, 534-540		4
132	Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. 2019 , 71, 99-112		16
131	Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. <i>Atherosclerosis</i> , 2019 , 289, 206-213	3.1	37
130	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. 2019 , 13, 580-585		10
129	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. 2019 , 56, 338-356		18
128	Lipoprotein(a) and mortality-a high risk relationship. 2019 , 14, 13-19		5
127	Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic. 2019 , 40, 94-99		2
126	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. 2020 , 382, 244-255		265
125	Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?. 2020 , 12,		11
124	Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. 2020, 511, 260-268		5
123	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. 2020 , 7, 88		29
122	Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. 2020 , 52, 162-177		13

121	The dedicated "Lp(a) clinic": A concept whose time has arrived?. <i>Atherosclerosis</i> , 2020 , 300, 1-9 3.1	24
120	What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?. 2020 , 63, 219-227	15
119	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. 2021 , 77, 1576-1589	18
118	Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 46	4
117	The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?. 2021 , 23, 97	3
116	Decreased plasma level of lipoprotein lipase predicted verbal disfluency in Chinese type 2 diabetes mellitus patients with early cognitive deficits. 2021 ,	1
115	Omega-3 Fatty Acids and Heart Disease. 1995 , 77-137	1
114	Atherosclerosis: The Genetic Analysis of a Multi-Factorial Disease. 1991 , 123-133	1
113	Recent advances in lipoprotein metabolism and the genetic dyslipoproteinemias. 1991 , 285, 237-44	4
112	Behandlung von Fettstoffwechselstfungen: Wann? Warum?. 1992 , 1-18	2
111	Lp(a) Lipoprotein: A Monogenic Risk Factor for Cardiovascular Disease. 1994 , 275-287	9
110	Antioxidant Protection of Low-Density Lipoprotein and Its Role in the Prevention of Atherosclerotic Vascular Disease. 1994 , 303-351	20
109	Lp(a) and the Fibrinolytic System. 1990 , 103-115	2
108	Effectiveness of Diet and Drugs in the Treatment of Patients with Elevated Lp(a) Levels. 1990 , 211-220	15
107	Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37 1994 , 269, 21820-21827	24
106	Interactions of low density lipoprotein2 and other apolipoprotein B-containing lipoproteins with lipoprotein(a) 1988 , 263, 6337-6343	39
105	Apolipoprotein(a) (Apo(a)) Glycoprotein Isoforms Result from Size Differences in Apo(a) mRNA in Baboons. 1989 , 264, 6013-6016	68
104	Expression of human apolipoprotein B90 in transgenic mice. Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein 1994 , 269, 24284-24289	37

103	Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins 1991, 266, 5480-5485		69
102	Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. <i>Journal of Lipid Research</i> , 2002 , 43, 234-244	6.3	32
101	Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. <i>Journal of Lipid Research</i> , 2001 , 42, 2058-2068	6.3	27
100	Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard. <i>Journal of Lipid Research</i> , 1999 , 40, 2255-2263	6.3	32
99	Molecular basis of an apolipoprotein[a] null allele: a splice sitemutation is associated with deletion of a single exon. <i>Journal of Lipid Research</i> , 1998 , 39, 1319-1326	6.3	15
98	Analytical capillary isotachophoresis of total plasma lipoproteins: a new tool to identify atherogenic low density lipoproteins. <i>Journal of Lipid Research</i> , 1999 , 40, 170-177	6.3	21
97	Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). <i>Journal of Lipid Research</i> , 1985 , 26, 1314-1323	6.3	160
96	Identification of a mouse monoclonal antibody, LHLP-1, specific for human Lp(a) <i>Journal of Lipid Research</i> , 1985 , 26, 540-548	6.3	28
95	Latex immunoassay of human serum Lp(a+) lipoprotein Journal of Lipid Research, 1985, 26, 267-269	6.3	14
94	High resolution plasma lipoprotein cholesterol profiles by a rapid, high volume semi-automated method <i>Journal of Lipid Research</i> , 1981 , 22, 1003-1014	6.3	40
93	Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. <i>Journal of Lipid Research</i> , 1996 , 37, 2029-2040	6.3	24
92	The interaction of human apoB-containing lipoproteins with mouse peritoneal macrophages: a comparison of Lp(a) with LDL <i>Journal of Lipid Research</i> , 1984 , 25, 283-287	6.3	32
91	Computerized rapid high resolution quantitative analysis of plasma lipoproteins based upon single vertical spin centrifugation. <i>Journal of Lipid Research</i> , 1982 , 23, 923-935	6.3	25
90	A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB <i>Journal of Lipid Research</i> , 1989 , 30, 1437-1443	6.3	56
89	Enzyme-linked immunoassay for Lp[a] Journal of Lipid Research, 1989, 30, 651-662	6.3	101
88	Screening for lipoprotein[a] elevations in plasma and assessment of size heterogeneity using gradient gel electrophoresis <i>Journal of Lipid Research</i> , 1989 , 30, 747-755	6.3	2 0
87	Characterization of five mouse monoclonal antibodies to apolipoprotein[a] from human Lp[a]: evidence for weak plasminogen reactivity <i>Journal of Lipid Research</i> , 1989 , 30, 23-37	6.3	28
86	Lipoprotein[a] is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus) <i>Journal of Lipid Research</i> , 1988 , 29, 1157-1170	6.3	66

85	Interaction of LDL, Lp[a], and reduced Lp[a] with monoclonal antibodies against apoB <i>Journal of Lipid Research</i> , 1988 , 29, 1-8	6.3	25
84	Isolation and characterization of the two major apoproteins in human lipoprotein [a] <i>Journal of Lipid Research</i> , 1986 , 28, 69-79	6.3	75
83	Factors influencing Lp[a]- particle size as determined by gradient gel electrophoresis <i>Journal of Lipid Research</i> , 1996 , 37, 1655-1663	6.3	5
82	Apolipoprotein[a] is not associated with apolipoprotein B in human liver. <i>Journal of Lipid Research</i> , 1994 , 35, 1896-1901	6.3	19
81	Quantification of cholesterol in all lipoprotein classes by the VAP-II method <i>Journal of Lipid Research</i> , 1994 , 35, 159-168	6.3	107
80	Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes <i>Journal of Lipid Research</i> , 1993 , 34, 509-517	6.3	83
79	Influence of short term dietary cholesterol and fat on human plasma Lp[a] and LDL levels <i>Journal of Lipid Research</i> , 1991 , 32, 1281-1289	6.3	54
78	Interaction of lipoprotein Lp[a] with the B/E-receptor: a study using isolated bovine adrenal cortex and human fibroblast receptors <i>Journal of Lipid Research</i> , 1990 , 31, 1247-1253	6.3	45
77	Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a] <i>Journal of Lipid Research</i> , 1990 , 31, 603-613	6.3	172
76	The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males. 1996 , 28, 757-64		22
75	Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes. 2001 , 12, 573-9		23
74	Expression of large genomic clones in transgenic mice: new insights into apolipoprotein B structure, function and regulation. 1998 , 9, 103-11		9
73	Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. 1996 , 16, 905-11		66
72	Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. 1997 , 96, 1390-7		85
71	Lipoprotein(a) in patients with acute cerebral ischemia. 1996 , 27, 1231-5		25
70	Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. 1987 , 80, 458-65		659
69			659

(2010-1991)

67	Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. 1991 , 87, 2153-61	321
66	Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. 1992 , 89, 1040-6	121
65	Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. 1992 , 89, 1166-71	116
64	Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). 1993 , 91, 397-401	94
63	Farnesoid X receptor represses hepatic human APOA gene expression. 2011 , 121, 3724-34	75
62	Fats and Oils in Human Health. 2008,	2
61	Serum lipoprotein(a) and its relation to left ventricular thrombus in patients with acute myocardial infarction. 2001 , 42, 5-14	2
60	Changes in the concentration and distribution of lipoprotein (a) in plasma after fat intake. 1995 , 2 Suppl 1, S17-21	2
59	Lipoprotein(a): important risk factor or passing fashion?. 1993 , 158, 512-4	3
58	Measuring lipoprotein(a): do it without ifs and buts. 2021 ,	1
57	Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery. 2021, 10,	1
56	Elevated Lp(a) Level and Heterozygous Factor V Mutation FV 1691 AG in a 26-Year-0ld Female with Ischemic Colitis. 2001 , 358-360	
55	A case of marked hyperlipoprotein(a)emia associated with nephrotic syndrome and advanced atherosclerosis. 2004 , 11, 293-8	3
54	Concentraciones elevadas de lipoproteña(a) en plasma en pacientes psiquificos: una posible contribuciñ al aumento del riesgo vascular. 2006 , 13, 301-306	
53	Genetics of lipoprotein disorders and coronary atheroma. 2007, 360-381	
53	Genetics of lipoprotein disorders and coronary atheroma. 2007 , 360-381 Apolipoproteins, quantitative lipoprotein traits and multifactorial hyperlipidaemia. 1987 , 130, 52-69	1
		1

Lipoprotein alterations in alcoholics. 1982, 41-46 49 Stoffwechsel. 1982, 675-711 48 Risikofaktoren und zerebrovaskulße Erkrankungen im h\u00e4beren Lebensalter. 1985, 27-45 47 Apolipoproteins in differential diagnosis of patients at high risk for atherosclerosis. 1987, 81-87 46 Apolipoprotein Polymorphism and Multifactorial Hyperlipidaemia. 1988, 74-86 45 Genetic Polymorphism of Lipoprotein (a). 1989, 64-69 44 Lipoprotein Lp(a): Structure and Metabolism. 1989, 56-63 43 Disorders of Lipoprotein Metabolism. 1990, 75-119 42 Lipoprotein- und Apoproteinspiegel bei alten Menschen. 1990, 27-37 41 Hyperlipoproteinemias. 1990, 347-380 40 Hyperlipoproteinemia of lipoprotein Lp(a). 1990, 136-143 39 38 Use of DNA technology in the diagnosis of occult atherosclerotic disease. 1991, 293-308 Apolipoproteins and coronary heart disease. 1991, 27-40 37 Lp(a)-Verteilung in der Dresdener Bevlkerung [DRECAN-Studie. 1993, 199-207 36 Beeinflu[®] das Lipoprotein (a) die Restenoserate nach Ballondilatation?. 1993, 252-258 35 Genetic Variation of the Apolipoprotein(a) Gene and Coronary Heart Disease. 1993, 139-158 34 Lipoprotein Metabolism. 1994, 29-51 33 Diagnostics of Lipids and Lipoproteins. 1994, 33-73 32

(2022-1995)

Elevated Levels of Lipoprotein (a) in Association with Cerebrovascular Saccular Aneurysmal Disease. **1995**, 37, 241???245

Arteriosklerose. 1998, 34-74 2 2 Tubular and Metabolic Dysfunction Following Transplantation. 1998, 1139-1152 27 Treatment of Hyperlipidemia in the Nephrotic Syndrome. 1998, 803-815 26 Sex Steroids and Endothelin. <i>Growth Hormone</i> , 1998, 25-44 25 Nephrotic Syndrome. 1998, 413-427 24 Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. <i>Growth Hormone</i> , 1999, 173-188 23 The Apolipoproteins (Taxonomy and Functions. 1983, 143-240 24 Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020, 14, 1-8 25 A new micromethod for routine measurement of serum LDL-apolipoprotein B <i>Journal of Lipid Research</i> , 1988, 29, 377-380 26 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. <i>EMBO Journal</i> , 1989, 8, 4035-40 27 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. 28 Anerican Journal of Human Genetics, 1992, 51, 829-40				
Tubular and Metabolic Dysfunction Following Transplantation. 1998, 1139-1152 Treatment of Hyperlipidemia in the Nephrotic Syndrome. 1998, 803-815 Sex Steroids and Endothelin. <i>Growth Hormone</i> , 1998, 25-44 Nephrotic Syndrome. 1998, 413-427 Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. <i>Growth Hormone</i> , 1999, 173-188 The Apolipoproteins Taxonomy and Functions. 1983, 143-240 Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020, 14, 1-8 A new micromethod for routine measurement of serum LDL-apolipoprotein B <i>Journal of Lipid Research</i> , 1988, 29, 377-380 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. <i>EMBO Journal</i> , 1989, 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	30	Assessment of Lipoproteins. 1997 , 170-217		1
Treatment of Hyperlipidemia in the Nephrotic Syndrome. 1998, 803-815 Sex Steroids and Endothelin. <i>Growth Hormone</i> , 1998, 25-44 Nephrotic Syndrome. 1998, 413-427 Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. <i>Growth Hormone</i> , 1999, 173-188 The Apolipoproteins Taxonomy and Functions. 1983, 143-240 Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020, 14, 1-8 A new micromethod for routine measurement of serum LDL-apolipoprotein B <i>Journal of Lipid Research</i> , 1988, 29, 377-380 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. <i>EMBO Journal</i> , 1989, 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	29	Arteriosklerose. 1998 , 34-74		2
26 Sex Steroids and Endothelin. <i>Growth Hormone</i> , 1998, 25-44 25 Nephrotic Syndrome. 1998, 413-427 24 Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. <i>Growth Hormone</i> , 1999, 173-188 23 The Apolipoproteins (Taxonomy and Functions. 1983, 143-240 22 Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020, 14, 1-8 2a A new micromethod for routine measurement of serum LDL-apolipoprotein B <i>Journal of Lipid Research</i> , 1988, 29, 377-380 2b Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. <i>EMBO Journal</i> , 1989, 8, 4035-40 2c Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	28	Tubular and Metabolic Dysfunction Following Transplantation. 1998 , 1139-1152		
25 Nephrotic Syndrome. 1998, 413-427 24 Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. Growth Hormone, 1999, 173-188 23 The Apolipoproteins (Taxonomy and Functions. 1983, 143-240 22 Lipoprotein(a) and its Clinical Importance. Medical Laboratory Journal, 2020, 14, 1-8 23 A new micromethod for routine measurement of serum LDL-apolipoprotein B Journal of Lipid Research, 1988, 29, 377-380 24 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO Journal, 1989, 8, 4035-40 25 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	27	Treatment of Hyperlipidemia in the Nephrotic Syndrome. 1998 , 803-815		
Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. <i>Growth Hormone</i> , 1999 , 173-188 The Apolipoproteins (Taxonomy and Functions. 1983 , 143-240 Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020 , 14, 1-8 A new micromethod for routine measurement of serum LDL-apolipoprotein B <i>Journal of Lipid Research</i> , 1988 , 29, 377-380 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. <i>EMBO Journal</i> , 1989 , 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	26	Sex Steroids and Endothelin. <i>Growth Hormone</i> , 1998 , 25-44		
The Apolipoproteins (Taxonomy and Functions. 1983, 143-240 Lipoprotein(a) and its Clinical Importance. Medical Laboratory Journal, 2020, 14, 1-8 A new micromethod for routine measurement of serum LDL-apolipoprotein B Journal of Lipid Research, 1988, 29, 377-380 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO Journal, 1989, 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	25	Nephrotic Syndrome. 1998 , 413-427		
Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020 , 14, 1-8 A new micromethod for routine measurement of serum LDL-apolipoprotein B <i>Journal of Lipid Research</i> , 1988 , 29, 377-380 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. <i>EMBO Journal</i> , 1989 , 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	24	Effects of Growth Hormone on Blood Coagulation and Fibrinolysis. <i>Growth Hormone</i> , 1999 , 173-188		
A new micromethod for routine measurement of serum LDL-apolipoprotein B Journal of Lipid Research, 1988, 29, 377-380 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO Journal, 1989, 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	23	The Apolipoproteins (Taxonomy and Functions. 1983 , 143-240		
20 Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO Journal, 1989, 8, 4035-40 Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	22	Lipoprotein(a) and its Clinical Importance. <i>Medical Laboratory Journal</i> , 2020 , 14, 1-8	0.2	
Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.	21		6.3	2
	20		13	11
	19		11	74
Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. <i>American Journal of Human Genetics</i> , 1991 , 48, 536-45	18		11	386
Immunohistochemical distribution of lipoprotein epitopes in xanthomata from patients with familial hypercholesterolemia. <i>American Journal of Pathology</i> , 1992 , 141, 99-106	17		5.8	19
16 Apolipoprotein disorders. <i>Research in Clinic and Laboratory</i> , 1982 , 12, 63-81	16	Apolipoprotein disorders. <i>Research in Clinic and Laboratory</i> , 1982 , 12, 63-81		5
Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol Journal of the American Heart Association. 2022. e023136	15	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol <i>Journal of the American Heart Association</i> , 2022 , e023136	6	1
,,,,,,,,,,	14	Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	O
Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus		international Southat of Motecular Sciences, 2022, 25,		

13	Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?. <i>Current Atherosclerosis Reports</i> , 2022 , 1	6	3
12	Lipoprotein(a) and ethnicities. <i>Atherosclerosis</i> , 2022 , 349, 42-52	3.1	5
11	The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target. <i>Atherosclerosis</i> , 2022 , 349, 1-6	3.1	2
10	Mendelian Randomization: Principles and its usage in Lp(a) research. <i>Atherosclerosis</i> , 2022 , 349, 36-41	3.1	7
9	Lipoprotîne(a) et risque cardiovasculaire. Revue Francophone Des Laboratoires, 2022, 2022, 57-67	O	
8	Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds. 2022, 80, 934-946		3
7	Premature Peripheral Atherosclerosis. 1993 , 1, 473-480		4
6	Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option. 2023, 24, 170		O
5	Lipoprotein(a) and Atherosclerotic Cardiovascular Diseases: Evidence from Chinese Population. 2023 , 3, 40-47		0
4	What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?. 2023, 3, 41		O
3	60 Years of Lp(a) Research: From Ouchterlonys Double Diffusion to Copy Number Variation and a Significant Risk Factor for CHD. 2023 , 1-37		О
2	Lp(a) Biochemistry, Composition, and Structure. 2023 , 39-54		O
1	Lipoprotein(a): cardiovascular risk and emerging therapies. 2023, 21, 259-268		O